Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer

Richard D. Kim, Shannon McDonough, Anthony B. El-Khoueiry, Tanios S. Bekaii-Saab, Stacey M. Stein, Vaibhav Sahai, George P. Keogh, Edward J. Kim, Ari D. Baron, Abby B. Siegel, Afsaneh Barzi, Katherine A. Guthrie, Milind Javle, Howard Hochster

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences